Results 11 to 20 of about 78,175 (168)

Biomimetic gold nanocages for overcoming chemoresistance of osteosarcoma by ferroptosis and immunogenic cell death

open access: yesMaterials & Design, 2021
Chemoresistance remains a huge challenge for the treatment of osteosarcoma (OS). Multiple mechanisms are involved in chemoresistance of cisplatin.
Chong Zhang   +6 more
doaj   +1 more source

Chemotherapy‐induced release of ADAM17 bearing EV as a potential resistance mechanism in ovarian cancer

open access: yesJournal of Extracellular Vesicles, 2023
Ovarian cancer (OvCa) is the gynaecological disorder with the poorest prognosis due to the fast development of chemoresistance. We sought to connect chemoresistance and cancer cell‐derived extracellular vesicles (EV).
Gerrit Hugendieck   +16 more
doaj   +1 more source

Predicting and Overcoming Taxane Chemoresistance [PDF]

open access: yesTrends in Molecular Medicine, 2021
Taxanes are microtubule-targeting drugs used as cytotoxic chemotherapy to treat most solid tumors. The development of resistance to taxanes is a major cause of therapeutic failure and overcoming chemoresistance remains an important challenge to improve patient's outcome.
Rodrigues-Ferreira, Sylvie   +3 more
openaire   +2 more sources

p53 Signaling on Microenvironment and Its Contribution to Tissue Chemoresistance

open access: yesMembranes, 2022
Chemoresistance persists as a significant, unresolved clinical challenge in many cancer types. The tumor microenvironment, in which cancer cells reside and interact with non-cancer cells and tissue structures, has a known role in promoting every aspect ...
Leonel Cardozo de Menezes e Souza   +4 more
doaj   +1 more source

Super-enhancers: a new frontier for epigenetic modifiers in cancer chemoresistance

open access: yesJournal of Experimental & Clinical Cancer Research, 2021
Although new developments of surgery, chemotherapy, radiotherapy, and immunotherapy treatments for cancer have improved patient survival, the emergence of chemoresistance in cancer has significant impacts on treatment effects.
Guo-Hua Li   +7 more
doaj   +1 more source

Emerging Significance of Ginsenosides as Potentially Reversal Agents of Chemoresistance in Cancer Therapy

open access: yesFrontiers in Pharmacology, 2021
Chemoresistance has become a prevalent phenomenon in cancer therapy, which alleviates the effect of chemotherapy and makes it difficult to break the bottleneck of the survival rate of tumor patients.
Jin-Feng Xu   +9 more
doaj   +1 more source

Chemoresistance and chemosensitization in cholangiocarcinoma

open access: yesBiochimica et Biophysica Acta (BBA) - Molecular Basis of Disease, 2018
One of the main difficulties in the management of patients with advanced cholangiocarcinoma (CCA) is their poor response to available chemotherapy. This is the result of powerful mechanisms of chemoresistance (MOC) of quite diverse nature that usually act synergistically.
Marin, Jose J. G.   +9 more
openaire   +3 more sources

Exploring role of 5hmC as potential marker of chemoresistance

open access: yesMolecular & Cellular Oncology, 2020
Chemoresistance remains to be a common and significant hurdle with all chemotherapies. Tumors gain resistance by acquiring additional mutations. Some of the chemoresistance mechanisms are known and can be tackled. However, the majority of chemoresistance
Suhas S. Kharat, Shyam K. Sharan
doaj   +1 more source

Identification of key genes and pathways related to cancer-associated fibroblasts in chemoresistance of ovarian cancer cells based on GEO and TCGA databases

open access: yesJournal of Ovarian Research, 2022
Background Studies have revealed the implications of cancer-associated fibroblasts (CAFs) in tumor progression, metastasis, and treatment resistance.
Li Han   +5 more
doaj   +1 more source

Role of SIRT1 in Chemoresistant Leukemia

open access: yesInternational Journal of Molecular Sciences, 2023
Leukemias of the AML, CML, and CLL types are the most common blood cancers worldwide, making them a major global public health problem. Furthermore, less than 24% of patients treated with conventional chemotherapy (low-risk patients) and 10–15% of patients ineligible for conventional chemotherapy (high-risk patients) survive five years.
Guadalupe Rosario Fajardo-Orduña   +4 more
openaire   +2 more sources

Home - About - Disclaimer - Privacy